AAV vector platform

Broad intellectual property around two original AAV vectors (AAV.GTX and AAV.GT5) with in vivo proof of concept data

Potential out-licensing opportunities to leverage the technology

Diverse portfolio of internal programs for CNS diseases and monogenic disorders

Cost advantage ; don’t have to pay large license fees, and have sufficient effect with less doses